Propofol sedation in colonoscopy: from satisfied patients to improved quality indicators

Figures & data

Table 1 Baseline characteristics of the propofol and control sedation groups

	Control group (n=27,802)	Propofol group (n=16,992)	P-value
Age	58.5±14.3	59.0±14.5
Sex (female)	13,646 (49.1%)	8,193 (48.2%)
Setting (outpatient)	23,742 (85.4%)	14,374 (84.6%)
Indication
Unknown	676 (2.4%)	475 (2.8%)	0.019
Personal history of polyps	1,867 (6.7%)	1,469 (8.6%)	<0.0001
Abdominal pain/diarrhea	7,147 (25.7%)	3,690 (21.7%)	<0.0001
IBD follow-up	442 (1.6%)	306 (1.8%)	0.094
Past colonic surgery	543 (2.0%)	211 (1.2%)	<0.0001
Anemia	3,190 (11.5%)	1,872 (11.0%)	0.14
Positive FOBT	1,823 (6.6%)	1,462 (8.6%)	<0.0001
Rectal bleed	4,685 (16.9%)	2,191 (12.9%)	<0.0001
Family history of CRC	2,767 (10.0%)	1,463 (8.6%)	<0.0001
Screening	668 (2.4%)	842 (5.0%)	<0.0001
Constipation	3,704 (13.3%)	1,236 (7.3%)	<0.0001
Imaging findings	1,285 (4.6%)	617 (3.6	<0.0001
Weight loss	801 (2.9%)	465 (2.7%)	0.38

Abbreviations: CRC, colorectal cancer; FOBT, fecal occult blood test; IBD, inflammatory bowel disease.

Table 2 Endoscopic findings in both sedation groups

	Control group	Propofol group	P-value
Cecal intubation rate
Overall	24,273 (87.3%)	15,368 (90.4%)	<0.0001
Adequate-preparation subgroup	17,548 (94.5%)	11,418 (97.8%)	<0.0001
Polyp-detection rate
Overall	5,814 (20.9%)	3,879 (22.8%)	<0.0001
Adequate-preparation subgroup	3,885 (20.9%)	2,577 (22.1%)	0.016
Terminal ileum-intubation rate
Overall	446 (1.6%)	1,085 (6.4%)	<0.0001
Adequate-preparation subgroup	321 (1.7%)	816 (7.0%)	<0.0001
Quality of bowel preparation
Adequate	18,574 (67.4%)	11,670 (69.0%)	<0.0001
Inadequate	9,001 (32.6%)	5,233 (31.0%)	<0.0001

Figure 1 Correlations between propofol dose and colonoscopy-quality indicators.

Notes: Propofol monotherapy improved colonoscopy-quality indicators in a dose-dependent manner. ^*P<0.01; ^**P<0.01.